--- canonical_name: Cagrilintide alternate_names: AM833, NNC0174-0833 canonical_topic: Cagrilintide for Health & Longevity short_topic_lc: cagrilintide creation_date: 2026-1006-1009 creator_ai_fullname: Opus 5.5 ep_keywords: Amylin Analogues, Amylin Receptor Agonists, Anti-Obesity Drugs, Weight Loss Drugs --- # Cagrilintide for Health & Longevity
Evidence Review created on 10/06/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 5.5 **Also known as:** AM833, NNC0174-0833 ## Motivation Cagrilintide is an experimental, once-weekly injectable medication that copies amylin, a hormone the pancreas releases together with insulin after meals to signal fullness. Popular weight-loss medications such as semaglutide act on a different gut hormone, whereas cagrilintide works through a separate set of fullness signals in the brainstem. That difference makes it of interest both on its own and as a partner to those medications. The idea is not new: a short-acting amylin copy has been prescribed to people with diabetes for about two decades, but it must be injected before every meal. Cagrilintide was engineered to last a full week, and after being studied mostly in combination with semaglutide, its developer has moved it into a dedicated program of trials testing it by itself. This review examines what is known about cagrilintide used alone: its effects on body weight, blood pressure and blood sugar, its side effects and safety signals, how it is dosed in trials, and what its experimental status means for adults weighing it as part of a long-term health and longevity strategy. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading These items give a high-level overview of cagrilintide and of long-acting amylin analogues (lab-made amylin copies) as a drug class. - [Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials](https://pubmed.ncbi.nlm.nih.gov/42452898/) - Alhazmi & le Roux, 2026 Current narrative review placing cagrilintide among long-acting amylin drugs, covering amylin physiology and cagrilintide's stand-alone weight-loss and tolerability data, nearly all from trials funded by its developer, Novo Nordisk. - [Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs](https://pubmed.ncbi.nlm.nih.gov/42586227/) - Fischer & Borner, 2026 Explains why amylin drugs cause nausea and how activity at the calcitonin receptor (a receptor also used by the bone hormone calcitonin) may shape tolerability versus GLP-1 (glucagon-like peptide-1, a gut fullness hormone) drugs. - [Development of Cagrilintide, a Long-Acting Amylin Analogue](https://pubmed.ncbi.nlm.nih.gov/34288673/) - Kruse et al., 2021 Primary chemistry paper by scientists at Novo Nordisk, the drug's developer, describing how amylin was modified to stop clumping and to last a week. - [Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?](https://pubmed.ncbi.nlm.nih.gov/41207308/) - Muskiet et al., 2026 Critical viewpoint proposing that amylin drugs such as cagrilintide may activate the renin-angiotensin system (a hormone cascade that raises blood pressure), a counterweight to reported blood-pressure benefits. - [Creating the amylin story](https://pubmed.ncbi.nlm.nih.gov/35183619/) - Lutz, 2022 Personal history by a leading amylin researcher tracing amylin from its discovery in pancreatic deposits to long-acting analogues such as cagrilintide. No cagrilintide or amylin content was found from Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine or Lifespan.io; as an investigational drug, cagrilintide has not yet been covered on these platforms. ## Grokipedia No dedicated Grokipedia article on cagrilintide exists. Grokipedia discusses cagrilintide only within its articles on the combination product cagrilintide/semaglutide (CagriSema) and on amylin. ## Examine No Examine article on cagrilintide exists. Examine.com does not typically cover prescription or investigational drugs, and cagrilintide is an investigational prescription drug candidate. ## ConsumerLab No ConsumerLab article on cagrilintide exists. ConsumerLab does not typically cover prescription medications, and cagrilintide is an investigational prescription drug that is not sold as a supplement. ## Systematic Reviews These systematic reviews and meta-analyses (pooled analyses of several trials) combine the randomized trials of cagrilintide alone, covering both weight loss and adverse events. - [Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis.](https://pubmed.ncbi.nlm.nih.gov/42180166/) - Rao et al., 2026 Pools four placebo-controlled trials; cagrilintide alone reduced weight by about six percentage points versus placebo, with modest blood-pressure effects and no glucose effect. - [Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.](https://pubmed.ncbi.nlm.nih.gov/42583410/) - Yaseen et al., 2026 Pools cagrilintide and CagriSema trials against placebo; reports blood-pressure reductions and a borderline excess of serious adverse events. Its discussion contains copy-editing errors. - [Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression.](https://pubmed.ncbi.nlm.nih.gov/41834765/) - Ahmed et al., 2026 Compares both regimens with semaglutide; cagrilintide alone gave comparable weight loss but more serious adverse events than semaglutide. - [Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis.](https://pubmed.ncbi.nlm.nih.gov/39676787/) - Dutta et al., 2024 Earliest pooled analysis of cagrilintide alone: weight loss similar to semaglutide or liraglutide, significantly less vomiting, and comparable serious adverse events. - [Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis.](https://pubmed.ncbi.nlm.nih.gov/42175595/) - Kamrul-Hasan et al., 2026 Compares many amylin-based drugs at once, including cagrilintide, for weight loss and gastrointestinal adverse events; high-dose cagrilintide raised constipation risk; certainty rated low. ## Mechanism of Action Cagrilintide is a lab-made version of amylin, a hormone the pancreas releases with insulin after meals. Amino-acid swaps stop it clumping, and a fatty-acid chain binds it to albumin (the main carrier protein in blood), slowing clearance ([Kruse et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34288673/)). - **Receptor targets:** It activates all three amylin receptors (AMY1, AMY2 and AMY3, each a calcitonin receptor paired with a RAMP, receptor activity-modifying protein) and the calcitonin receptor alone, making it a dual agonist that switches on both receptor types ([Fletcher et al., 2021](https://pubmed.ncbi.nlm.nih.gov/33727283/); [Cao et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40204768/)). - **Brain action:** In brainstem appetite centers these receptors signal fullness and end meals earlier; in mice lacking the helper proteins for AMY1 and AMY3, cagrilintide was less potent ([Carvas et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40609154/)). - **Gut and pancreas:** Amylin signaling slows stomach emptying and suppresses glucagon (a hormone that raises blood sugar) after meals. - **Pharmacokinetics (how the body handles the drug):** Half-life (time for blood levels to halve) is 159–195 hours, peaking 24–72 hours after injection ([Enebo et al., 2021](https://pubmed.ncbi.nlm.nih.gov/33894838/)). Albumin binding keeps it mostly in the bloodstream. Protein-cutting enzymes trim it from both ends ([Alhalabi et al., 2026](https://pubmed.ncbi.nlm.nih.gov/41702251/)); CYP (cytochrome P450, liver drug-processing) enzymes likely play no role; kidney or liver impairment did not change exposure ([Nielsen et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42228334/)). - **Competing view:** Some researchers argue calcitonin-receptor activity may shape both efficacy and nausea, possibly through aversive brainstem circuits, and that selective amylin agonists (acting only on amylin receptors) could separate fullness from malaise ([Fischer & Borner, 2026](https://pubmed.ncbi.nlm.nih.gov/42586227/)). ## Historical Context & Evolution Amylin was identified in 1987 as the main component of amyloid (clumped protein) deposits in the pancreas of people with type 2 diabetes; later work showed it is also a circulating hormone that ends meals, slows stomach emptying and restrains glucagon ([Lutz, 2022](https://pubmed.ncbi.nlm.nih.gov/35183619/)). Its first therapeutic use was diabetes: pramlintide, a non-clumping amylin copy, received US approval in 2005 as an add-on to mealtime insulin ([Symlin label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4aea30ff-eb0d-45c1-b114-3127966328ff)). Because it lasts only hours, it must be injected before each meal, and weight loss with it was modest, so the rapid success of GLP-1 drugs shifted attention away from amylin for years ([Alhazmi & le Roux, 2026](https://pubmed.ncbi.nlm.nih.gov/42452898/)). Novo Nordisk then engineered cagrilintide for once-weekly use ([Kruse et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34288673/)). It was first studied mainly as a partner to semaglutide (the CagriSema combination), and stand-alone data came from a phase 2 trial and single-drug arms of larger trials. Interest in health optimization grew because it reaches appetite through a pathway distinct from GLP-1 drugs and, in trials, caused less vomiting. Opinion has shifted on two fronts. In 2025 the developer advanced cagrilintide alone into its own phase 3 program after reviewing stand-alone results ([Novo Nordisk, 2025](https://www.biospace.com/press-releases/novo-nordisk-presents-phase-3-data-for-next-generation-amylin-cagrilintide-leading-to-advancement-into-dedicated-clinical-programme)). In 2026 the combination failed to match tirzepatide in a head-to-head trial, tempering expectations for the combination ([Novo Nordisk, 2026](https://www.biospace.com/press-releases/novo-nordisk-a-s-cagrisema-demonstrated-23-weight-loss-in-an-open-label-head-to-head-redefine-4-trial-in-people-with-obesity-the-primary-endpoint-was-not-achieved)). ## Expected Benefits ### High 🟩 🟩 🟩 #### Body Weight Reduction Cagrilintide alone lowers body weight by increasing fullness and reducing meal size. Placebo-controlled trials from two investigator groups showed this: the phase 2 dose-finding trial led by Lau (706 adults, 26 weeks) ([Lau et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34798060/)) and the cagrilintide arm of the phase 3 REDEFINE 1 trial led by Garvey (68 weeks) ([Garvey et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40544433/)). Both were funded by Novo Nordisk. Loss was smaller than with semaglutide 2.4 mg in the same trial ([Busetto et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42503495/)). **Magnitude:** 6.08 percentage points more weight loss than placebo in pooled trials (95% CI [confidence interval, the range likely to contain the true effect] 4.14 to 8.02) ([Rao et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42180166/)); in REDEFINE 1, 11.5% vs 3.0% with placebo at 68 weeks regardless of adherence, and 31.0% vs 5.2% reached at least 15% loss, not compared between groups ([Novo Nordisk, 2025](https://www.biospace.com/press-releases/novo-nordisk-presents-phase-3-data-for-next-generation-amylin-cagrilintide-leading-to-advancement-into-dedicated-clinical-programme)). ### Medium 🟩 🟩 #### Lower Blood Pressure Weight loss, and possibly direct vascular effects, lowers blood pressure. A meta-analysis of randomized controlled trials (RCTs, studies that assign treatment by chance) found modest falls in systolic (upper-number) and diastolic (lower-number) pressure with cagrilintide alone versus placebo ([Yaseen et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42583410/)), and the REDEFINE 1 cagrilintide arm showed the same ([Verma et al., 2026](https://pubmed.ncbi.nlm.nih.gov/41328546/)). Blood pressure was a secondary outcome, and all trials came from one sponsor's program. Amylin may also activate the renin-angiotensin system, which could offset part of this effect ([Muskiet et al., 2026](https://pubmed.ncbi.nlm.nih.gov/41207308/)). **Magnitude:** Systolic pressure 3.30 mm Hg lower than placebo (95% CI 0.81 to 5.78) and diastolic pressure 1.70 mm Hg lower (95% CI 0.34 to 3.05) in pooled trials ([Yaseen et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42583410/)); in REDEFINE 1, systolic 2.4 mm Hg lower (95% CI 0.8 to 4.1) and diastolic 1.3 mm Hg lower (95% CI 0.1 to 2.4) than placebo at 68 weeks ([Verma et al., 2026](https://pubmed.ncbi.nlm.nih.gov/41328546/)). ### Low 🟩 #### Improved Blood Sugar Control in Type 2 Diabetes In a 32-week type 2 diabetes trial, HbA1c (a three-month blood-sugar average) fell with cagrilintide alone, without placebo ([Frias et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37364590/)). Placebo-controlled phase 3 REIMAGINE 2 included cagrilintide alone, but its abstract omits that comparison ([Buse et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42251859/)). Without diabetes, HbA1c did not change ([Rao et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42180166/)). **Magnitude:** HbA1c fell 0.9 percentage points with cagrilintide and 1.8 with semaglutide over 32 weeks; not compared between groups, and no placebo group ([Frias et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37364590/)). ### Speculative 🟨 #### Bone Preservation During Weight Loss Calcitonin-receptor activation may slow bone breakdown, and pramlintide lowered a bone-resorption marker. No cagrilintide bone data exist yet; the basis is mechanistic ([Alhazmi & le Roux, 2026](https://pubmed.ncbi.nlm.nih.gov/42452898/)). #### Fat-Selective Weight Loss In rodents, cagrilintide reduced fat mass while preserving lean tissue. No human body-composition data for cagrilintide alone are published; the basis is animal data only ([Alhazmi & le Roux, 2026](https://pubmed.ncbi.nlm.nih.gov/42452898/)). #### Kidney Protection Lower weight and blood pressure could reduce albumin leakage into urine. A completed phase 2 kidney trial with a cagrilintide arm has posted no results; the basis is mechanistic only ([NCT06131372](https://clinicaltrials.gov/study/NCT06131372)). ## Benefit-Modifying Factors - **Genetic polymorphisms:** No gene variants are known to change response. Because cagrilintide is cleared by protein-cutting enzymes rather than CYP enzymes, common drug-metabolism gene variants are not expected to matter; amylin-receptor gene variants have not been studied. - **Baseline biomarkers:** A higher starting BMI (body mass index, weight relative to height) made weight and waist targets less likely ([Busetto et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42503495/)). HbA1c was unchanged without diabetes ([Rao et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42180166/)) but fell in type 2 diabetes ([Frias et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37364590/)). - **Sex:** Women made up about two-thirds of REDEFINE 1 participants, but sex-specific results for the cagrilintide arm have not been reported ([Busetto et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42503495/)). - **Pre-existing conditions:** In type 2 diabetes, cagrilintide alone produced 8.1% loss at 32 weeks ([Frias et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37364590/)); no study has compared its effect with and without diabetes. In type 1 diabetes, the older amylin drug pramlintide produced modest loss ([Alhazmi & le Roux, 2026](https://pubmed.ncbi.nlm.nih.gov/42452898/)). - **Age:** Trial participants were mostly middle-aged, and older adults are under-represented; in older adults the share of weight lost as muscle matters more than total loss, so body composition determines net benefit. ## Potential Risks & Side Effects ### High 🟥 🟥 🟥 #### Gastrointestinal Adverse Events Nausea, constipation, diarrhea and vomiting are the most common effects, reflecting slowed stomach emptying and brainstem signaling. They appeared in trials led by Lau ([Lau et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34798060/)), Garvey ([Garvey et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40544433/)) and Frias ([Frias et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37364590/)), all funded by Novo Nordisk. Events were mostly mild to moderate and transient, and rose with dose. Vomiting was less frequent than with semaglutide or liraglutide in pooled data ([Dutta et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39676787/)). **Magnitude:** At 2.4 mg in the phase 2 trial, nausea affected 32 of 102 participants vs 18 of 101 on placebo, constipation 17 vs 7, and vomiting 9 vs 3, not compared between groups ([NCT03856047 results](https://clinicaltrials.gov/study/NCT03856047)); in REDEFINE 1, nausea led to stopping treatment in 1.0% vs 0.1% on placebo, not compared between groups ([Novo Nordisk, 2025](https://www.biospace.com/press-releases/novo-nordisk-presents-phase-3-data-for-next-generation-amylin-cagrilintide-leading-to-advancement-into-dedicated-clinical-programme)). ### Medium 🟥 🟥 #### Injection-Site Reactions Redness, itching and local reactions at the injection site were more frequent with cagrilintide than with placebo in the phase 2 trial led by Lau ([Lau et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34798060/)). They were generally mild and did not occur with placebo injections. The finding comes from a single trial; phase 3 stand-alone data on this outcome are not yet published. **Magnitude:** At 2.4 mg, an injection-site reaction was recorded in 12 of 102 participants and injection-site redness in 7 of 102, vs 0 of 101 on placebo for each, not compared between groups ([NCT03856047 results](https://clinicaltrials.gov/study/NCT03856047)). #### Fatigue Tiredness was more common with cagrilintide, especially at 4.5 mg, in the phase 2 trial led by Lau ([Lau et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34798060/)). It plausibly reflects lower food intake. It is a single-trial finding not yet confirmed in phase 3 publications. **Magnitude:** Fatigue in 20 of 101 participants at 4.5 mg and 10 of 102 at 2.4 mg, vs 3 of 101 on placebo, not compared between groups ([NCT03856047 results](https://clinicaltrials.gov/study/NCT03856047)). ### Low 🟥 #### Serious Adverse Events ⚠️ Conflicted Meta-analyses disagree. A borderline excess appeared versus placebo ([Yaseen et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42583410/)) and an excess versus semaglutide ([Ahmed et al., 2026](https://pubmed.ncbi.nlm.nih.gov/41834765/)). Dutta et al. found no difference but pooled only three small early trials ([Dutta et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39676787/)). Net reading: a possible small excess that remains unconfirmed. **Magnitude:** Risk ratio (RR, how many times more often an event occurs) 1.46 versus placebo (95% CI 1.00 to 2.13) ([Yaseen et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42583410/)) and RR 1.83 versus semaglutide (95% CI 1.03 to 3.24) ([Ahmed et al., 2026](https://pubmed.ncbi.nlm.nih.gov/41834765/)); neither source reports absolute event rates. #### Low Blood Sugar With Insulin or Insulin-Releasing Drugs Amylin analogues lower after-meal glucose; with insulin, pramlintide causes severe hypoglycemia (dangerously low blood sugar) and carries a boxed warning ([Symlin label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4aea30ff-eb0d-45c1-b114-3127966328ff)). This evidence is indirect, from a different compound. Cagrilintide's diabetes trial without insulin reported no clinically significant hypoglycemia ([Frias et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37364590/)). **Magnitude:** Not quantified in available studies. No published trial has reported hypoglycemia rates for cagrilintide alone combined with insulin or sulfonylureas (oral medications that make the pancreas release insulin). #### Gallbladder Events Rapid weight loss raises the risk of gallstones. In the phase 2 trial, isolated serious gallbladder events occurred with cagrilintide and none with placebo; the numbers are too small to compare ([Lau et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34798060/)). **Magnitude:** One serious case of cholelithiasis (gallstones) at 4.5 mg (101 participants) and one of biliary colic (gallstone pain) at 1.2 mg (102 participants) vs none in 101 on placebo; not compared between groups ([NCT03856047 results](https://clinicaltrials.gov/study/NCT03856047)). ### Speculative 🟨 #### Renin-Angiotensin System Activation Muskiet et al. hypothesize that amylin agonists activate this blood-pressure-raising hormone cascade, which could undermine heart and kidney benefits. The basis is mechanistic and animal data only ([Muskiet et al., 2026](https://pubmed.ncbi.nlm.nih.gov/41207308/)). #### Lean Mass Loss Substantial weight loss from any cause removes some muscle and bone. No body-composition data for cagrilintide alone are published; the basis is extrapolation from other weight-loss treatments. ## Risk-Modifying Factors - **Genetic polymorphisms:** No variants are known to alter cagrilintide's side effects; it bypasses CYP metabolism, so common drug-metabolism gene variants should not change exposure. - **Baseline biomarkers:** Near-normal HbA1c with insulin or sulfonylurea use raises hypoglycemia risk. Reduced kidney function did not change drug exposure ([Nielsen et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42228334/)) but increases vulnerability to dehydration from vomiting. - **Sex:** Sex-specific side-effect rates for cagrilintide have not been reported; women were the majority in trials, so the reported profile mainly reflects women. - **Pre-existing conditions:** Gastroparesis (slow stomach emptying), gallstone history, insulin-treated diabetes and hypoglycemia unawareness (not sensing low blood sugar) raise risk; pramlintide's label lists gastroparesis and hypoglycemia unawareness as contraindications ([Symlin label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4aea30ff-eb0d-45c1-b114-3127966328ff)). - **Age:** Older adults face greater consequences from dehydration, muscle loss and reduced food intake, and they were under-represented in trials. ## Key Interactions & Contraindications - **GLP-1 receptor agonists (drugs mimicking GLP-1: semaglutide, liraglutide, tirzepatide):** Monitor. Additive nausea, vomiting and constipation; cagrilintide did not change semaglutide blood levels ([Enebo et al., 2021](https://pubmed.ncbi.nlm.nih.gov/33894838/)). Escalating one drug at a time limits side effects. - **Insulin and sulfonylureas (insulin glargine, insulin lispro, glimepiride, glipizide):** Caution (theoretical). Risk of severe hypoglycemia, by analogy to pramlintide's boxed warning, whose label cuts mealtime insulin by 50% at initiation ([Symlin label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4aea30ff-eb0d-45c1-b114-3127966328ff)); frequent glucose checks during escalation mitigate it. - **Oral drugs needing rapid or steady absorption (acetaminophen, levothyroxine, oral contraceptives, warfarin):** Monitor (theoretical). Slowed stomach emptying may delay or blunt absorption. Pramlintide's label advises taking such drugs 1 hour before or 2 hours after injection ([Symlin label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4aea30ff-eb0d-45c1-b114-3127966328ff)). - **Gut-slowing prescription drugs (anticholinergics, which block a gut-moving nerve signal, such as oxybutynin; opioid pain relievers such as oxycodone):** Caution (theoretical). Worsened constipation and nausea; pramlintide's label advises against agents that alter gut motility ([Symlin label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4aea30ff-eb0d-45c1-b114-3127966328ff)). Stool softeners or fiber mitigate it. - **Blood-pressure medications that block the renin-angiotensin system (lisinopril, losartan) or increase urine output (hydrochlorothiazide):** Monitor (theoretical). Additive pressure lowering and, with vomiting or diarrhea, low blood pressure or kidney injury. Home blood-pressure checks mitigate it. - **Over-the-counter sedating antihistamines (allergy or sleep aids such as diphenhydramine, doxylamine) and loperamide (an antidiarrheal):** Caution (theoretical). Their gut-slowing effects add to constipation and bloating. Non-sedating alternatives avoid this. - **Over-the-counter NSAIDs (non-steroidal anti-inflammatory pain relievers such as ibuprofen, naproxen):** Caution (theoretical). Kidney injury risk rises when vomiting or diarrhea causes dehydration. Pausing them during gastrointestinal illness and maintaining fluids mitigates it. - **Glucose-lowering supplements (berberine, chromium, cinnamon extract):** Monitor (theoretical). Additive glucose lowering, relevant mainly with insulin or sulfonylureas, raising hypoglycemia risk. Fingerstick glucose checks mitigate it. - **Blood-pressure-lowering supplements (garlic extract, beetroot nitrate, magnesium):** Monitor (theoretical). Additive pressure lowering, with dizziness on standing. Home blood-pressure tracking mitigates it. - **Viscous fiber supplements (glucomannan, psyllium):** Monitor (theoretical). Additive fullness and slowed emptying may worsen bloating or, without enough water, constipation. Ample fluid intake mitigates it. - **Alcohol and prolonged fasting or very-low-calorie diets:** Caution (theoretical). Hypoglycemia with glucose-lowering drugs, dehydration, and compounded undernutrition from reduced food intake. Adequate protein and fluids mitigate it. **Populations who should avoid Cagrilintide:** - Pregnant or breastfeeding women and those planning pregnancy: no human data; the phase 2 trial enrolled only women of non-childbearing potential ([NCT03856047](https://clinicaltrials.gov/study/NCT03856047)). - People under 18 years: safety in children and adolescents is still being tested ([NCT07253285](https://clinicaltrials.gov/study/NCT07253285)). - People with confirmed gastroparesis or hypoglycemia unawareness: Avoid (theoretical), by analogy to pramlintide's contraindications ([Symlin label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4aea30ff-eb0d-45c1-b114-3127966328ff)). - People with type 1 diabetes on insulin: Avoid (theoretical), given pramlintide's boxed warning for severe hypoglycemia in type 1 diabetes ([Symlin label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4aea30ff-eb0d-45c1-b114-3127966328ff)). - People with a current or past eating disorder: Avoid (theoretical), because strong appetite suppression can reinforce restrictive eating. - Anyone with prior hypersensitivity to cagrilintide or its formulation. ## Risk Mitigation Strategies Doses and timings below follow common practice unless cited. - **Slow dose escalation:** Reduces gastrointestinal adverse events; trials raised the dose over 16 weeks to 2.4 mg ([Garvey et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40544433/)). Holding a step an extra 4 weeks when nausea persists limits discontinuation. - **Smaller, lower-fat meals:** Lessens nausea and bloating from slowed stomach emptying; stopping at first fullness matters most in the 1–3 days after each injection. - **Fluid and fiber targets:** Prevents constipation and dehydration-related kidney injury; common targets are about 2–3 liters of fluid and 25–30 g of fiber daily, with a stool softener if needed. - **Insulin and sulfonylurea adjustment:** Prevents hypoglycemia; pramlintide's label cuts mealtime insulin by 50% at initiation ([Symlin label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4aea30ff-eb0d-45c1-b114-3127966328ff)), with glucose checks before meals and at bedtime during escalation. - **Protein intake and resistance training:** Limits lean mass loss; common targets are about 1.2–1.6 g protein per kg body weight daily and resistance training 2–3 times weekly. - **Injection-site rotation:** Reduces injection-site reactions; sites rotate between abdomen, thigh and upper arm, each injection 2–3 cm from the last. - **Gallbladder warning signs:** Limits harm from gallstone complications; right-upper-abdominal pain lasting over 30 minutes, fever or yellowing skin are reasons to seek prompt medical advice. - **Hydration stop rule:** Prevents kidney injury; dosing is usually paused, and medical advice sought, if vomiting or diarrhea prevents keeping fluids down for more than 24 hours. - **Pharmaceutical-grade sourcing only:** Avoids contamination and dosing errors from unregulated "research peptide" products, which the FDA (US Food and Drug Administration) has targeted with warning letters ([FDA warning letter, 2024](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/summit-research-peptides-695607-12102024)). ## Therapeutic Protocol Doses below are cited to trial regimens; other parameters without a citation (timing, titration step size, missed-dose handling, cycling) reflect common practice. - **Standard regimen:** 2.4 mg once weekly by subcutaneous (under-the-skin) injection after a 16-week escalation, as in REDEFINE 1 and the RENEW phase 3 program ([Garvey et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40544433/); [Novo Nordisk, 2025](https://www.biospace.com/press-releases/novo-nordisk-presents-phase-3-data-for-next-generation-amylin-cagrilintide-leading-to-advancement-into-dedicated-clinical-programme)). - **Escalation steps:** REDEFINE 1 escalated from 0.25 mg to 2.4 mg over 16 weeks ([Garvey et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40544433/)), in roughly 4-week steps; the phase 2 trial started at 0.6 mg and doubled every 2 weeks ([NCT03856047](https://clinicaltrials.gov/study/NCT03856047)). - **Higher-dose alternative:** 4.5 mg weekly gave the most weight loss in the phase 2 trial but more fatigue and injection-site reactions ([Lau et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34798060/)); development settled on 2.4 mg. - **Combination approach:** Developer-led trials pair 2.4 mg cagrilintide with 2.4 mg semaglutide weekly (CagriSema) for greater loss ([Garvey et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40544433/)); stand-alone use trades some efficacy for less vomiting. - **Who popularized it:** Novo Nordisk developed and tested cagrilintide; no longevity clinic or practitioner has published a protocol. Self-dosing with gray-market "research" vials follows no published protocol. - **Time of day:** With a week-long half-life, time of day matters little; a fixed weekday is used, and some prefer evening injection so peak nausea falls during sleep. - **Half-life:** 159–195 hours, with peak levels 1–3 days after injection ([Enebo et al., 2021](https://pubmed.ncbi.nlm.nih.gov/33894838/)); by standard pharmacokinetic principles, a stable blood level forms after about 4–5 weeks at a fixed dose. - **Single versus split dose:** Given as a single weekly injection; splitting has not been studied and offers no expected advantage given the long half-life. - **Genetic polymorphisms:** No pharmacogenetic (gene-based) dose adjustments exist; CYP variants do not apply because the peptide is degraded by protein-cutting enzymes. - **Sex differences:** No sex-specific dosing exists and sex-specific responses have not been reported; women of childbearing potential use reliable contraception in trials. - **Age:** No age-based dose change is defined; older adults may hold each escalation step longer and emphasize protein intake and strength training. - **Baseline biomarkers:** A very high starting BMI predicts a lower chance of reaching healthy weight targets ([Busetto et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42503495/)); HbA1c fell in type 2 diabetes but not in people without diabetes. - **Pre-existing conditions:** No dose change is needed for kidney or liver impairment ([Nielsen et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42228334/)); insulin users need insulin reduction, and gastroparesis is a reason to avoid it. ## Discontinuation & Cycling - **Intended duration:** Cagrilintide is studied as long-term, continuous treatment for a chronic condition; stand-alone trials ran 26–68 weeks ([Lau et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34798060/); [Garvey et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40544433/)). - **Weight regain after stopping:** No stand-alone cagrilintide withdrawal data are published; after stopping semaglutide, people regained two-thirds of lost weight within a year ([Wilding et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35441470/)), and similar regain is expected. - **Withdrawal effects:** No physical withdrawal syndrome is known; given the week-long half-life, appetite is expected to return gradually over several weeks. - **Tapering:** No taper is required for safety; some step down through lower doses over 4–8 weeks to soften the return of appetite. - **Restarting after a gap:** After more than about 2 missed weeks, restarting at a lower dose and re-escalating reduces nausea. - **Cycling:** Cycling is not supported; no data suggest tolerance develops, and on-off use invites weight regain. ## Sourcing and Quality - **No approved product:** No approved cagrilintide product exists ([FDA warning letter, 2024](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/summit-research-peptides-695607-12102024)); it is not yet available outside clinical trials ([Beverly Hills Rejuvenation Center](https://www.bhrcenter.com/peptides/cagrilintide/)), so legitimate access means trial enrollment. - **Gray-market "research peptides":** Online sellers market cagrilintide labeled "research use only"; the FDA treats such products as unapproved new drugs intended for human use and has issued warning letters ([FDA warning letter, 2024](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/summit-research-peptides-695607-12102024)). - **What to look for:** Purity certificates from gray-market vendors are not independently verifiable; sterility, bacterial endotoxin (fever-causing contaminant) testing and identity confirmation by mass spectrometry (a molecular-weight test) are minimum quality markers, and none is assured. - **Compounding pharmacies and brands:** No reputable compounding pharmacy or brand offers cagrilintide; a clinic tracking the drug warns that any source claiming to sell it is unregulated ([Beverly Hills Rejuvenation Center](https://www.bhrcenter.com/peptides/cagrilintide/)). - **Formulation:** Trial supply was given by pen injector ([NCT03856047](https://clinicaltrials.gov/study/NCT03856047)); gray-market powders that require mixing add dosing-error and contamination risk. ## Practical Considerations - **Time to effect:** Weight loss accumulates during the 16-week escalation and continued through 68 weeks in REDEFINE 1 ([Garvey et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40544433/)); the 26-week phase 2 trial already showed clear loss ([Lau et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34798060/)). - **Common pitfalls:** Escalating too fast, undereating protein, neglecting fluids, and stopping abruptly once goal weight is reached are frequent mistakes, each linked to side effects or weight regain. - **Regulatory status:** Unapproved; cagrilintide alone is in phase 3, and the developer reports submitting CagriSema to the FDA in December 2025 ([Novo Nordisk, 2025](https://www.prnewswire.com/news-releases/novo-nordisk-files-for-fda-approval-of-cagrisema-the-first-once-weekly-combination-of-glp1-and-amylin-analogues-for-weight-management-302645862.html)); the FDA does not publish pending applications, and its 2026 approvals list has no entry ([FDA approvals, 2026](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)). - **Access and cost:** No legal commercial source exists, so no price can be compared; clinical-trial enrollment is the only legitimate access. - **Payer incentives:** Weekly injectable obesity drugs cost far more than lifestyle programs or generic drugs, so insurers and national health systems have a financial incentive to restrict coverage, a potential structural bias in guideline and coverage decisions. ## Interaction with Foundational Habits - **Sleep:** Indirect. No sleep studies exist for cagrilintide; weight loss can ease obstructive sleep apnea (breathing pauses during sleep), while nausea or reflux after injection may disturb sleep. Smaller evening meals during escalation reduce night-time symptoms. - **Nutrition:** Potentiating, with depletion risk. Reduced appetite and slowed stomach emptying favor smaller meals but risk low protein and micronutrient intake. Protein at each meal, fiber, fluids and nutrient-dense foods offset this; fatty or fried meals worsen nausea. - **Exercise:** Indirect, potentially blunting. A calorie deficit can reduce training energy and lean mass. Resistance training 2–3 times weekly helps preserve muscle; hard sessions fit best outside the 1–2 days of peak nausea after injection. - **Stress management:** Indirect. Amylin acts on brain reward circuits in animals, which may dampen stress-driven eating; no human cortisol or stress-response data exist. Mindful-eating practices complement the drug's fullness signal. ## Monitoring Protocol & Defining Success Before starting, a baseline assessment establishes reference values: fasting body weight, waist and height, seated blood pressure, HbA1c and fasting glucose, kidney function, and, where available, a body-composition scan. For people using insulin or sulfonylureas, a glucose-monitoring plan agreed with the prescriber is part of the baseline, because hypoglycemia is the main laboratory-detectable safety risk. Ongoing monitoring follows this cadence: weight and blood pressure weekly at home during the 16-week escalation and monthly afterward; HbA1c and kidney function at 3 months, then every 6 months; fingerstick glucose daily during escalation for insulin or sulfonylurea users; body composition at 6 and 12 months. Success is commonly defined as at least 5% weight loss, a co-primary endpoint threshold in REDEFINE 1 ([Garvey et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40544433/)), with lean mass largely preserved and side effects tolerable. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | |-----------|--------------------------|-----------------|---------------| | Body weight | No established target; track percentage change from own baseline | Expected to change (efficacy) | Fasting, same scale and time each week; at least 5% loss was a trial co-primary endpoint ([Garvey et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40544433/)) | | Waist-to-height ratio | No established target; track change from own baseline | Expected to change (central fat) | Measured at the navel after exhaling; a later REDEFINE 1 analysis used below 0.53 as an exploratory target ([Busetto et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42503495/)) | | Blood pressure | Below 130/80 mm Hg (outcome threshold used by Busetto et al., 2026) | Expected to change; safety check for dizziness with blood-pressure drugs | Source: [Busetto et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42503495/); conventional reference range: below 120/80 mm Hg is classed as normal; seated, after 5 minutes' rest | | HbA1c | 4.0–5.6% (standard reference range) | Expected to change in diabetes; safety check for hypoglycemia with glucose-lowering drugs | No fasting needed; reflects about 3 months of glucose | | Fasting glucose | 70–99 mg/dL (standard reference range) | Safety check (hypoglycemia with insulin or sulfonylureas) | 8-hour fast; fingerstick checks before meals during escalation add detail | | eGFR | Above 60 mL/min/1.73 m² (standard reference range) | Safety check (dehydration-related kidney injury from vomiting or diarrhea) | eGFR (estimated glomerular filtration rate, a kidney-filtering measure); rechecked promptly after prolonged vomiting or diarrhea | | Lean mass by DXA | No established target; track the share of lost weight that is lean tissue | Expected to change (body composition) | DXA (dual-energy X-ray absorptiometry, a low-dose body-composition scan); same machine each time | Qualitative markers: - Appetite, fullness and reduced "food noise" (intrusive food thoughts) - Nausea, bowel habits and bloating - Energy levels and fatigue - Strength and exercise performance - Sleep quality, especially after injection day - Relationship with food and absence of restrictive-eating patterns ## Emerging Research - **RENEW 1 (obesity without diabetes):** Phase 3, 300 participants, cagrilintide versus placebo for 64 weeks, primary endpoint weight change ([NCT07220642](https://clinicaltrials.gov/study/NCT07220642)). Positive: confirms stand-alone efficacy at phase 3 standard. Null: would undercut cagrilintide as a stand-alone option. - **RENEW 2 (obesity with type 2 diabetes):** Phase 3, 330 participants, 64 weeks, primary endpoint weight change ([NCT07220759](https://clinicaltrials.gov/study/NCT07220759)). Positive: extends evidence to diabetes and adds glucose data. Null: would confine benefit to people without diabetes. - **RAMBO bone trial:** Phase 1, 144 postmenopausal women, cagrilintide versus semaglutide, CagriSema or placebo for 68 weeks; primary endpoint hip bone density ([NCT07010432](https://clinicaltrials.gov/study/NCT07010432)). Positive: would upgrade the bone-preservation benefit. Null: would remove it. - **RASMUS muscle trial:** Phase 1, 100 participants, 52 weeks, measuring muscle insulin sensitivity, composition and function ([NCT07527195](https://clinicaltrials.gov/study/NCT07527195)). Positive: supports fat-selective loss. Null or harm: strengthens the lean-mass concern. - **Tolerability after GLP-1 intolerance:** Randomized feasibility study, 114 participants who stopped GLP-1 drugs for gastrointestinal effects, 26 weeks ([NCT07607587](https://clinicaltrials.gov/study/NCT07607587)). Positive: defines a niche for intolerant people. Null: weakens the tolerability rationale. - **Kidney trial (completed):** Phase 2, 626 participants with chronic kidney disease and type 2 diabetes, including a cagrilintide-alone arm; urine albumin primary endpoint ([NCT06131372](https://clinicaltrials.gov/study/NCT06131372)). Completed November 2025, no results posted. - **Alcohol-related liver disease trial (completed):** Phase 2, 270 participants, including a cagrilintide-alone arm, measuring a liver-scarring marker and alcohol use ([NCT06409130](https://clinicaltrials.gov/study/NCT06409130)). Completed January 2026, no results posted. - **REDEFINE 3 heart outcomes:** Phase 3, 7,101 participants with cardiovascular disease, CagriSema versus placebo, major cardiovascular events ([NCT05669755](https://clinicaltrials.gov/study/NCT05669755)). Positive: first hard-outcome evidence, though for the combination. Null: weakens longevity claims. - **Competing amylin drugs:** Other long-acting amylin drugs, such as the selective agonist eloralintide and petrelintide, report weight loss of similar or greater size in phase 1–2 trials ([Alhazmi & le Roux, 2026](https://pubmed.ncbi.nlm.nih.gov/42452898/)); results could favor or displace cagrilintide's dual-receptor design. - **Renin-angiotensin hypothesis:** Muskiet et al. propose biomarker studies of renin and aldosterone in amylin-treated people ([Muskiet et al., 2026](https://pubmed.ncbi.nlm.nih.gov/41207308/)); results could confirm a heart and kidney risk or reveal additional benefit. ## Conclusion Cagrilintide is a once-weekly injectable copy of amylin, a fullness hormone from the pancreas, and it remains an experimental drug approved nowhere. Its main benefit is well supported: compared with inactive injections, it produced meaningful, sustained weight loss, somewhat less than the leading gut-hormone drugs but with less vomiting. A modest blood-pressure benefit is moderately supported, and better blood sugar control in type 2 diabetes rests on limited data. Protection of bone, muscle or kidneys remains theoretical. Its downsides are mainly digestive, chiefly nausea, constipation and diarrhea, along with injection-site reactions and tiredness, usually mild and concentrated in the early weeks of dose increases. Some combined analyses of several trials suggest a small excess of serious health events that has not been confirmed. Combined with insulin, low blood sugar is a real concern carried over from an older drug in the same family. Almost all human evidence comes from studies paid for and run by the drug's maker, and none measures long-term outcomes such as heart attacks, disability or lifespan. For health-focused adults, access is the most consequential practical fact: outside clinical trials, the only products available are unregulated "research" chemicals of unknown purity, which regulators have formally warned sellers about. Experience with similar drugs shows that weight returns once treatment stops, so any benefit depends on continued use. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**